Experimental cancer treatments

IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042

Retrieved on:

Thursday, May 20, 2021

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Health sciences, Experimental cancer treatments, Oncolytic virus, Virotherapy, Virus

In the case of ICVB-1042, we incorporate a series of mutations to optimize potency, selectivity and tumor tropism, and potentially enable both intratumoral and intravenous administration.

Key Points:

In the case of ICVB-1042, we incorporate a series of mutations to optimize potency, selectivity and tumor tropism, and potentially enable both intratumoral and intravenous administration.
The abstract shared at ASCO describes the first pair of mutations that we introduced into ICVB-1042, which improve tumor selectivity without impacting replicative efficiency or sacrificing lytic potency.
IconOVir\xe2\x80\x99s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O\xe2\x80\x99Shea, Ph.D., of the Salk Institute.
It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients.

Global Oncolytic Virus Cancer Therapy Pipeline Insight Report 2021: Key Players, Key Products, Research Programmes - ResearchAndMarkets.com

Retrieved on:

Monday, May 10, 2021

Oncology, Health, Other Science, Clinical trials, Science, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Medicine, Experimental cancer treatments, Virotherapy, Biotechnology, Oncolytic virus, Adenoviridae, Therapy, Virus, Genelux Corporation, Oncolytic herpes virus

b'The "Oncolytic Virus Cancer Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Oncolytic Virus Cancer Therapy - Pipeline Insight, 2021 report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape.

Key Points:

b'The "Oncolytic Virus Cancer Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Oncolytic Virus Cancer Therapy - Pipeline Insight, 2021 report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape.
It further highlights the inactive pipeline products in this space.\nThe companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D.
The therapies under development are focused on novel approaches for Oncolytic Virus Cancer Therapy.\nThis segment of the Oncolytic Virus Cancer Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
Phase III include, CG Oncology.\nOncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial

Retrieved on:

Wednesday, May 5, 2021

Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.

Key Points:

Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.
A total of approximately 20 patients will receive TILT-123 as a monotherapy over a three-month period.
It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).\nDocrates Cancer Center is a private, Finnish-owned, international hospital in Helsinki specializing in individual and comprehensive cancer care.
Docrates provides services for cancer patients throughout the treatment chain from diagnosis to treatments and follow-up.

Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors

Retrieved on:

Tuesday, May 4, 2021

Medicine, Clinical medicine, Health, Vaccination, Oncolytic virus, Experimental cancer treatments, Virus, Vaccine, Cancer, Melanoma, Virotherapy, Therapeutic vaccines

b'FARMINGDALE, N.Y., May 4, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice President, Oncology.

Key Points:

b'FARMINGDALE, N.Y., May 4, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice President, Oncology.
In her new role, Dr. Kaufmann will lead the Company\'s oncology franchise, overseeing the development of oncolytic virus therapies targeting breast cancer, melanoma, and prostate cancer.
Doing so, Codagenix can use its platform to customize viruses for specific cancer types.
"Codagenix is utilizing a highly innovative approach to attenuate viruses capable of inducing potent prophylactic and therapeutic immune responses.

Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Thursday, April 29, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Virotherapy, Oncolytic virus, Immunotherapy, Experimental cancer treatments, Biotechnology, CAN-3110, Candel Therapeutics, CAN-3110, CANDEL THERAPEUTICS

b'Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.

Key Points:

b'Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.
For more information on this clinical study, please visit https://www.clinicaltrials.gov/ct2/show/NCT03152318?term=candel&draw=3\nCandel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications.
To learn more, visit www.candeltx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005404/en/\n'

Global $962 Million Oncolytic Virus Therapies Market to 2030

Retrieved on:

Monday, April 26, 2021

Medicine, Experimental cancer treatments, Clinical medicine, Health sciences, Biotechnology, Oncolytic virus, Virotherapy, Virus

b'DUBLIN, April 26, 2021 /PRNewswire/ -- The "Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com\'s offering.\nOncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.\nOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body.

Key Points:

b'DUBLIN, April 26, 2021 /PRNewswire/ -- The "Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com\'s offering.\nOncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.\nOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body.
Oncolytic virotherapy is a form of gene therapy that used nature\'s material (virus) to find and destroy malignant cells.
Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.\nWithin the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region.
Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.\nKey Questions Answered in this Report:\nWhat are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?\nWhat are the key development strategies being implemented by the major players in order to sustain in the competitive market?\nWhat are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?\nHow is each segment of the market expected to grow during the forecast period 2020-2030?\nWho are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?\nWhat are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?\nWhat is the COVID-19 impact on the global oncolytic virus therapies market?\nWhich companies are anticipated to be highly disruptive in the future, and why?\nWhat are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?\nWhat are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?\nWhat are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?\nHow is each segment of the market expected to grow during the forecast period 2020-2030?\nThe following are the segment types:\n'

Global Oncolytic Virus Therapies Market Report 2021-2030: Lucrative Opportunities in Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies - ResearchAndMarkets.com

Retrieved on:

Tuesday, April 20, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Branches of biology, Health sciences, Biotechnology, Experimental cancer treatments, Molecular biology, Oncolytic virus, Virotherapy, Emerging technologies, Virus, Gene therapy, Therapy

These therapies aim at modifying genetic material for the treatment of a disease.

Key Points:

These therapies aim at modifying genetic material for the treatment of a disease.
Oncolytic virotherapy is a form of gene therapy that used nature\'s material (virus) to find and destroy malignant cells.
Oncolytic virus therapy is "a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person\'s genes".
Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.\nWithin the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region.

IconOVir Bio Announces Formation of Scientific Advisory Board

Retrieved on:

Tuesday, April 20, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Oncolytic virus, Experimental cancer treatments, Virotherapy, Biotechnology

b'IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the formation of its Scientific Advisory Board (SAB).

Key Points:

b'IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the formation of its Scientific Advisory Board (SAB).
He currently serves on several editorial and advisory boards, and he previously served on the Board of Directors for the American Association for Cancer Research.
IconOvir\xe2\x80\x99s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O\xe2\x80\x99Shea, Ph.D., of the Salk Institute.
For more information, please visit www.iconovir.com and follow IconOVir on LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005269/en/\n'

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on:

Monday, April 19, 2021

Virotherapy, Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Akseli Hemminki, Transgene SA

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points:

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer

Retrieved on:

Wednesday, April 14, 2021

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer treatments, Adenoviridae, Experimental cancer treatments, Virotherapy, Biotechnology, Oncolytic adenovirus, Orphan drugs, Oncolytic virus, Pembrolizumab, Cytokine

During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.

Key Points:

During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.
The heart of our approach revolves around the use of oncolytic adenoviruses armed with cytokines to boost the patient\xe2\x80\x99s immune response towards the tumor, enabling it to find and destroy cancer cells.
TILT\xe2\x80\x99s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines; TNF alpha and IL-2.
It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).